Dr. Ron Najafi, CEO of NovaBay® Pharmaceuticals, Inc. (AMEX & TSX: NBY, http://www.novabay.com), a clinical stage biopharmaceutical company developing non-antibiotic anti-infective compounds that do not develop resistance, for the treatment or prevention of a wide range of bacterial, fungal, and viral infections, will present at the 4th Annual Summer Technology Conference hosted by Security Research Associates, Inc. The conference will be held on Monday, August 18, 2008 at the Omni Hotel in San Francisco.
Conference attendees will include a select group of institutional portfolio managers and analysts, and will feature CEOs and CFOs from some of the fastest growing companies in the technology sector. SRA has arranged for webcasting of company presentations during this event. To access the lobby page for the webcast of presenting companies please go to: http://www.wsw.com/webcast/sra7/
Dr. Najafi will provide a corporate overview and review NovaBay’s business development strategy and product development candidates in the areas of hospital infections, catheter-associated urinary tract infections, and dermatology. NovaBay® has a collaboration agreement with the leading eye care company in the world, Alcon Laboratories, Inc., to research, develop, and commercialize the company’s Aganocide® compounds to treat eye, ear, and sinus infections, as well as develop the next generation contact lens solution. NovaBay® has also partnered with Kinetic Concepts, Inc. (KCI), to develop an anti-infective solution for use with KCI’s wound healing system. NovaBay® has also recently announced positive results from a Phase IIa study of AgaNase™ for the nasal decolonization of Staph, including MRSA. The company is also developing product candidate opportunities for the dermatology market, details of which Dr. Najafi will provide during the presentation.
About Security Research Associates, Inc.
Security Research Associates, Inc. (SRA) was founded in San Francisco in 1980 and, today, offers investment banking and M&A services as well as institutional brokerage services. A boutique firm by design, SRA works with a select group of portfolio managers from around the country and focuses on technology and life science companies in the micro and small cap arenas. For more information about SRA see our web site at www.sracap.com or call us at 415-925-0346.
About NovaBay® Pharmaceuticals, Inc.
NovaBay® Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay® has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocide® compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay® believes that Aganocide® compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, Staphylococcus aureus (including resistant strains known as MRSA) without developing resistance, a serious problem that invariably plagues all antibiotics. NovaBay® has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide® compounds in the eye, ear and sinus, and in contact lens solutions. The company also has a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay’s NeutroPhase product in wound care applications.
NovaBay™, Aganocide®, AgaNase™, and NeutroPhase™ are trademarks of NovaBay® Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projection, and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay’s product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay® disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
The Investor Relations Group
Adam Holdsworth / Erica Ruderman / Brett Foley
Janet Vasquez / Laura Colontrelle